Galmed Pharmaceuticals Ltd. GPH.F Stock
Galmed Pharmaceuticals Ltd. Price Chart
Galmed Pharmaceuticals Ltd. GPH.F Financial and Trading Overview
| Galmed Pharmaceuticals Ltd. stock price | 0.36 EUR |
| Previous Close | 3.42 EUR |
| Open | 3.4 EUR |
| Bid | 3.4 EUR x 50000 |
| Ask | 3.44 EUR x 50000 |
| Day's Range | 3.4 - 3.4 EUR |
| 52 Week Range | 0.32 - 12.22 EUR |
| Volume | 1 EUR |
| Avg. Volume | 24 EUR |
| Market Cap | 5.73M EUR |
| Beta (5Y Monthly) | 1.112323 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GPH.F Valuation Measures
| Enterprise Value | -6372002 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.4764574 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.471 |
Trading Information
Galmed Pharmaceuticals Ltd. Stock Price History
| Beta (5Y Monthly) | 1.112323 |
| 52-Week Change | -41.79% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.22 EUR |
| 52 Week Low | 0.32 EUR |
| 50-Day Moving Average | 4.05 EUR |
| 200-Day Moving Average | 5.51 EUR |
GPH.F Share Statistics
| Avg. Volume (3 month) | 24 EUR |
| Avg. Daily Volume (10-Days) | 20 EUR |
| Shares Outstanding | 1.68M |
| Float | 1.36M |
| Short Ratio | N/A |
| % Held by Insiders | 13.83% |
| % Held by Institutions | 10.78% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.67% |
| Return on Equity (ttm) | -74.55% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -13527000 EUR |
| Net Income Avi to Common (ttm) | -13553000 EUR |
| Diluted EPS (ttm) | -6.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 12.15M EUR |
| Total Cash Per Share (mrq) | 7.23 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.582 |
| Book Value Per Share (mrq) | 7.136 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14744000 EUR |
| Levered Free Cash Flow (ttm) | -9880625 EUR |
Profile of Galmed Pharmaceuticals Ltd.
| Country | Germany |
| State | N/A |
| City | Tel Aviv |
| Address | 16 Tiomkin Street |
| ZIP | 6578317 |
| Phone | 972 3 693 8448 |
| Website | https://www.galmedpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Q&A For Galmed Pharmaceuticals Ltd. Stock
What is a current GPH.F stock price?
Galmed Pharmaceuticals Ltd. GPH.F stock price today per share is 0.36 EUR.
How to purchase Galmed Pharmaceuticals Ltd. stock?
You can buy GPH.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galmed Pharmaceuticals Ltd.?
The stock symbol or ticker of Galmed Pharmaceuticals Ltd. is GPH.F.
Which industry does the Galmed Pharmaceuticals Ltd. company belong to?
The Galmed Pharmaceuticals Ltd. industry is Biotechnology.
How many shares does Galmed Pharmaceuticals Ltd. have in circulation?
The max supply of Galmed Pharmaceuticals Ltd. shares is 6.04M.
What is Galmed Pharmaceuticals Ltd. Price to Earnings Ratio (PE Ratio)?
Galmed Pharmaceuticals Ltd. PE Ratio is now.
What was Galmed Pharmaceuticals Ltd. earnings per share over the trailing 12 months (TTM)?
Galmed Pharmaceuticals Ltd. EPS is -2.3 EUR over the trailing 12 months.
Which sector does the Galmed Pharmaceuticals Ltd. company belong to?
The Galmed Pharmaceuticals Ltd. sector is Healthcare.